RegentAtlantic Capital’s AstraZeneca AZN Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2022
Q3
$858K Sell
7,827
-31
-0.4% -$3.93K 0.03% 340
2022
Q2
$1.04M Sell
7,858
-40
-0.5% -$5.25K 0.03% 310
2022
Q1
$1.05M Buy
7,898
+14
+0.2% +$1.68K 0.03% 313
2021
Q4
$918K Buy
7,884
+383
+5% +$45.1K 0.03% 339
2021
Q3
$901K Buy
7,501
+536
+8% +$62.4K 0.03% 322
2021
Q2
$834K Buy
6,965
+146
+2% +$16K 0.03% 323
2021
Q1
$678K Sell
6,819
-228
-3% -$22.9K 0.02% 333
2020
Q4
$705K Buy
7,047
+137
+2% +$14.5K 0.03% 288
2020
Q3
$757K Sell
6,910
-75
-1% -$8.34K 0.03% 267
2020
Q2
$739K Buy
6,985
+95
+1% +$9.81K 0.04% 260
2020
Q1
$615K Sell
6,890
-76
-1% -$7.16K 0.05% 251
2019
Q4
$695K Buy
6,966
+344
+5% +$32.4K 0.04% 272
2019
Q3
$590K Sell
6,622
-94
-1% -$8.15K 0.04% 281
2019
Q2
$554K Sell
6,716
-234
-3% -$18.3K 0.04% 286
2019
Q1
$562K Sell
6,950
-465
-6% -$36.7K 0.04% 281
2018
Q4
$563K Sell
7,415
-380
-5% -$29.7K 0.05% 265
2018
Q3
$617K Buy
7,795
+262
+3% +$19.8K 0.05% 269
2018
Q2
$529K Sell
7,533
-289
-4% -$20.8K 0.05% 267
2018
Q1
$547K Sell
7,822
-13
-0.2% -$900 0.05% 269
2017
Q4
$544K Buy
7,835
+1
+0% +$67 0.04% 273
2017
Q3
$531K Buy
7,834
+45
+0.6% +$2.84K 0.05% 270
2017
Q2
$531K Sell
7,789
-298
-4% -$19.5K 0.05% 268
2017
Q1
$504K Sell
8,087
-965
-11% -$56.2K 0.05% 269
2016
Q4
$495K Sell
9,052
-968
-10% -$55K 0.05% 271
2016
Q3
$658K Buy
10,020
+769
+8% +$50.3K 0.07% 242
2016
Q2
$559K Sell
9,251
-252
-3% -$14.6K 0.05% 251
2016
Q1
$535K Sell
9,503
-1,231
-11% -$74K 0.06% 243
2015
Q4
$729K Sell
10,734
-1,108
-9% -$72.6K 0.08% 213
2015
Q3
$754K Sell
11,842
-873
-7% -$57.4K 0.07% 209
2015
Q2
$810K Sell
12,715
-1,280
-9% -$87.6K 0.07% 205
2015
Q1
$958K Sell
13,995
-1,832
-12% -$127K 0.08% 192
2014
Q4
$1.11M Sell
15,827
-230
-1% -$16.5K 0.09% 176
2014
Q3
$1.15M Sell
16,057
-2,720
-14% -$199K 0.11% 166
2014
Q2
$1.4M Sell
18,777
-2,433
-11% -$176K 0.13% 152
2014
Q1
$1.38M Sell
21,210
-9,438
-31% -$610K 0.13% 147
2013
Q4
$1.82M Buy
30,648
+790
+3% +$42.9K 0.18% 126
2013
Q3
$1.55M Buy
29,858
+1,243
+4% +$62.4K 0.17% 132
2013
Q2
$1.35M Buy
+28,615
New +$1.46M 0.16% 132

Other funds holding AZN

RegentAtlantic Capital's AZN Position: Q3 2022 in Review

RegentAtlantic Capital reduced its AstraZeneca (AZN) stake by 0.39% in Q3 2022, selling an estimated $3.93K and leaving 7,827 shares worth $858K. The position accounts for 0.03% of the portfolio, ranked #340.

RegentAtlantic Capital first reported a position in AZN in Q2 2013 and has held it in 38 quarters since. The position peaked at $1.82M in Q4 2013. 965 funds tracked by Wall St. Rank hold AZN as of Q3 2022.

  • RegentAtlantic Capital held 7,827 shares of AstraZeneca worth $858K as of Q3 2022.
  • RegentAtlantic Capital sold 31 AstraZeneca shares in Q3 2022, an estimated $3.93K.
  • AstraZeneca made up 0.03% of RegentAtlantic Capital's portfolio in Q3 2022, its #340 holding.
  • RegentAtlantic Capital first reported a position in AstraZeneca in Q2 2013 and has held it in 38 quarters since.
  • RegentAtlantic Capital's AstraZeneca position peaked at $1.82M in Q4 2013.
  • 965 funds tracked by Wall St. Rank held AstraZeneca as of Q3 2022.

Based on RegentAtlantic Capital's 13F filing for Q3 2022, filed 14 Nov 2022.